NDA 208259 · Alcon Labs INC
Rocklatan
Latanoprost, Netarsudil Dimesylate · Ophthalmic · Prostaglandin Analog
Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Mar 12, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
253
56 Phase 3, 9 recruiting
FAERS reports
967
205 serious, 45 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 27, 2026.
1. INDICATIONS AND USAGE ROCKLATAN is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ROCKLATAN ® is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )
Mechanism: ROCKLATAN is comprised of two components: netarsudil and latanoprost. Each of these two components decreases elevated IOP. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and glaucomatous visual field loss. ROCKLATAN is believed to reduce IOP by increasing the outflow of aqueous humor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 12, 2019 Original approval · New Combination and New Formulation or New Manufacturer LabelLetterReview
1 products under this application
- ROCKLATAN · LATANOPROST 0.005%; NETARSUDIL DIMESYLATE EQ 0.02% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Latanoprost" as an intervention, any sponsor and status, largest first.
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02674854 · 750 participants · Start Feb 2016 · Primary completion Mar 2017
Drug: PG324 Ophthalmic Solution 0.02%/0.005%; Netarsudil (AR-13324) ophthalmic solution 0.02% and 1 more · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00690794 · 726 participants · Start Jul 2008 · Primary completion May 2009
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®); Latanoprost ophthalmic solution 0.005% (XALATAN®) · For: Open-angle Glaucoma; Ocular Hypertension
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02558400 · 718 participants · Start Sep 18, 2015 · Primary completion May 17, 2017
Drug: PG324 Ophthalmic Solution 0.02%/0.005%; Netarsudil (AR-13324) Ophthalmic Solution 0.02% and 1 more · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Phase III Clinical Trial of TRAVATAN Z in Ocular Surface HealthPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00761319 · 705 participants · Start Oct 2008 · Primary completion Sep 2009
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®); Latanoprost ophthalmic solution 0.005% (XALATAN®) · For: Open-angle Glaucoma; Ocular Hypertension
- MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT04630808 · 696 participants · Start Nov 9, 2020 · Primary completion Apr 11, 2025
Drug: NCX 470 0.1%; Latanoprost 0.005% · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Chandler, Arizona; Phoenix, Arizona · 88 sites in all
- Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT04445519 · 691 participants · Start Jun 1, 2020 · Primary completion Sep 16, 2022
Drug: NCX 470 0.065% (initial phase of trial); Latanoprost 0.005% (initial phase of trial) and 3 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT03657797 · 656 participants · Start Aug 1, 2018 · Primary completion Aug 23, 2019
Drug: NCX 470; Latanoprost 0.005% · For: Glaucoma, Open-Angle; Hypertension, Ocular
Sites: Austin, Texas
- Next Generation RocklatanPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06441643 · 646 participants · Start Sep 4, 2024 · Primary completion Nov 14, 2025
Drug: AR-17043 Ophthalmic Solution; PG043 Ophthalmic Solution and 4 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Phoenix, Arizona; Garden Grove, California · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ocular hyperaemia149
- eye irritation115
- vision blurred102
- conjunctival hyperaemia94
- eye pain88
- lacrimation increased79
- product dose omission issue76
- eye pruritus64
- drug ineffective42
- death38
- intraocular pressure increased35
- fatigue32
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 59 |
| 2020 | 151 |
| 2021 | 81 |
| 2022 | 78 |
| 2023 | 105 |
| 2024 | 166 |
| 2025 | 188 |
| 2026 | 138 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rocklatan (Netarsudil Mesylat/Latanoprost)
2024 spending
$167M
Beneficiaries
78,022
329,580 claims
Per beneficiary
$2,146
$132.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $49,651,592 |
| 2021 | $83,890,591 |
| 2022 | $118,576,611 |
| 2023 | $146,478,267 |
| 2024 | $167,398,355 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, et al. · Graefes Arch Clin Exp Ophthalmol 2024 · Randomized Controlled Trial, Multicenter Study
- Effect of Latanoprost on Choroidal Thickness.
Sahinoglu-Keskek N, Canan H · J Glaucoma 2018 · Clinical Trial
- Latanoprost in hemifacial spasm.
Crevits L, Goethals M, Libbrecht N, et al. · Prostaglandins Other Lipid Mediat 2002 · Clinical Trial
- Does using topical latanoprost affect subfoveal choroidal thickness?
Duru Z, Özsaygl C, Ulusoy DM, et al. · Cutan Ocul Toxicol 2019 · Controlled Clinical Trial
- The effect of latanoprost on intraocular pressure during 2 years of treatment.
Hedman K, Watson PG, Alm A · Surv Ophthalmol 2002 · Clinical Trial, Clinical Trial, Phase III
Sponsor: Alcon Labs INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.